ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2681

Blocking the Serum Protease Inhibitor Activity of Plasminogen Activator Inhibitor-1 Protects Mice From Development of Glomerulonephritis in a Model of Lupus Nephritis

Brian Naiman1, Tracy Delaney1, Lily Cheng2, Philip Brohawn2, Chris Morehouse2, Christopher Groves1, Isabelle de-Mendez3, Dominic Corkill4, Anthony Coyle5, Ronald Herbst1 and Jane Connor1, 1Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Gaithersburg, MD, 2Translational Sciences, MedImmune, LLC, Gaithersburg, MD, 3Research, MedImmune, LLC, Cambridge, United Kingdom, 4Respiration, Inflammation and Autoimmunity, MedImmune, LLC, Cambridge, United Kingdom, 5Centers for Therapeutic Innovation, Pfizer, Inc. (formerly MedImmune LLC, Gaithersburg, MD, USA), Cambridge, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Animal models, lupus nephritis and proteinuria

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Lupus nephritis is an autoimmune disorder which is characterized by extracellular matrix accumulation driven by immune complex deposition and in which thrombosis and sclerosis play a role in the development of nephropathy. Plasminogen activator inhibitor-1 (PAI-1) is the major inhibitor of pro-fibrinolytic plasminogen activators uPA and tPA and its expression has been shown to be increased in renal biopsies obtained from patients with lupus nephritis. Several studies utilizing transgenic mice (KO or over-expressing) in models of lupus nephritis have demonstrated a role for PAI-1 in the kidney pathology associated with these models.  The purpose of these studies was to evaluate the contribution of PAI-1 inhibition of PAs to pathological changes in the kidney in an accelerated model of mouse lupus nephritis.

Methods: An adenovirus encoding IFNa was injected into lupus-prone NZB/W mice resulting in an accelerated model of glomerulonephritis. A monoclonal antibody that selectively prevents the binding of PAI-1 to its target PAs was administered ip twice weekly beginning at the time of adv-IFNa administration. Effect of PAI-1 neutralization on development of proteinuria, gene and protein expression and histological changes in the kidney, and protein circulating in the plasma was assessed. Potential effects on immune cell expansion observed in this model were evaluated by FACS analysis. In vitro, the effect of blocking PAI-1 on extracellular matrix (ECM) degradation was evaluated in rat mesangial cells.

Results: PAI-1 was shown to be dramatically increased in the kidney (mRNA, IHC, ELISA) as well as in the plasma (ELISA) of diseased mice.  Inhibition of the PAI-1/PA interaction via treatment with the anti-PAI-1 antibody provided dose-dependent protection against the development of proteinuria and changes in sodium excretion. These effects were associated with normalization of fibrinolysis, ECM, cytokine and chemokine genes as well as histological changes in the glomerulus of the kidney.  Anti-PAI-1 treatment provided concentration-dependent degradation of ECM in rat mesangial cells providing further mechanistic support for the in vivo findings.

Conclusion: These data suggest that interfering with the PAI-1/PA interaction provides protection from the pathological changes in the kidney in this murine model downstream of immune complex deposition in the kidney.


Disclosure:

B. Naiman,

MedImmune, LLC,

3;

T. Delaney,

MedImmune, LLC,

3;

L. Cheng,

MedImmune, LLC,

3;

P. Brohawn,

MedImmune,

3;

C. Morehouse,

MedImmune,

3;

C. Groves,

MedImmune, LLC,

3;

I. de-Mendez,

MedImmune, LLC,

3;

D. Corkill,

MedImmune, LLC,

3;

A. Coyle,

MedImmune, LLC,

3;

R. Herbst,

MedImmune, LLC,

3;

J. Connor,

MedImmune, LLC,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/blocking-the-serum-protease-inhibitor-activity-of-plasminogen-activator-inhibitor-1-protects-mice-from-development-of-glomerulonephritis-in-a-model-of-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology